Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of semaglutide injection versus Ozempic in type 2 diabetes mellitus
CTR20232700Phase 3Completed
- Sponsor
- Huisheng Biopharmaceutical
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Huisheng Biopharmaceutical. Started Nov 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20232700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232700.